TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The ORTIZ Study: Optimising RASi Therapy With SZC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Able and willing to provide written informed consent~2. Adults ≥ 18years old~3. Type 2 Diabetes~4. CKD defined as eGFR 25-60ml/min~5. Albuminuria with uACR measured at \>33.9.mg/mmol (300mg/g)~6. On a stable (\>4 weeks) of sub-maximal RASi dose, defined as any ACE or ARB dose up to and including 50% of maximum dose with evidence of hyperkalaemia potassium level \>5.0mmol/l OR not currently on RASi therapy due to documented issues of hyperkalaemia in the past necessitating RASi discontinuation~Exclusion Criteria:~1. Active malignancy~2. Patients who lack capacity to give informed consent~3. GI disturbance/chronic diarrhoea/stoma~4. Subjects with a life expectancy of less than 3 months.~5. Women who are pregnant, lactating, planning to become pregnant or unwilling to use effective methods of contraception during the study.~6. Presence of any condition which, in the opinion of the investigator, places the subject at undue risk or potentially jeopardizes the quality of the data to be generated including NYHA class III/IV.~7. History of acute eGFR fall with RASi therapy (\>30% in eGFR on initiation of RASi therapy)~8. Known hypersensitivity or previous anaphylaxis to SZC or Irbesartan~9. Hypotension: BP \<120/70mm/hg at screening despite no antihypertensive agent use~10. Uncontrolled Blood pressure: BP \>170/110 at screening~11. Evidence of prolonged QT on ECG QTc(f)\>550msec~12. History of QT prolongation associated with other medications that required discontinuation of that medication~13. Treatment with lithium, or dual blockade with ACEi and ARB or mineralocorticoid inhibitor~14. History of congenital long QT syndrome~15. Symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained ventricular tachycardia. Subjects with atrial fibrillation controlled by medication are permitted~16. Current or recent (within 3 months) participation in a clinical trial involving an investigational medicinal product.~17. Current treatment with a potassium binder medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SZC (Type: EXPERIMENTAL): 3 month treatment using Sodium zirconium cyclocilicate. Doses of 5 or 10g once daily will be used. The dose will be titrated according to potassium levels performed at clinic visits
- Placebo (Type: PLACEBO_COMPARATOR): 3 month treatment using matched placebo. Doses of 5 or 10g once daily will be used. The dose will be titrated according to potassium levels performed at clinic visits

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Haploidentical Stem Cell Transplant With or Without NK Cell Infusion in AML and MDS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of AML or MDS~* Patients not in remission at the time of transplant~* Age 18-75~* ECOG performance status \<2~* Availability of a family HLA haploidentical donor, eligible to donate both marrow cells and unstimulated lymphocytes (1 apheresis procedure at day +7) .~Exclusion Criteria:~* Positive serologic markers for human immunodeficiency virus (HIV)~* Acute hepatitis B virus (HBV) or acute hepatitis C virus (HCV) infection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Haplo-stem cell transplant followed by NK infusion (Type: EXPERIMENTAL): Haplo stem cell transplant (from bone marrow or apheresis) is followed by a haplo-NK cell infusion (target dose ≥1\*106/kg b.w.) at day 7.~Unstimulated haplo-NK cells are collected through apheresis Mononuclear cells are then subjected to a preliminary negative selection of CD3+ cells and to a subsequent positive selection of CD56+ cells. CD3 negative/CD56 positive cells are infused
- Haplo-stem cell transplant (Type: ACTIVE_COMPARATOR): Patients in this arm receive standard haplo stem cell transplant (from bone marrow or apheresis) transplant without subsequent NK cell infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Polyamine-low Diet to Prevent Postoperative Pain After Cholecystectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* laparoscopic cholecystectomy~* ambulatory surgery~* agreeing to follow a polyamine-low diet with Polydol plus~Exclusion Criteria:~* Pregnancy~* Contra-indication to a non-steroidal anti-inflammatory, to tramadol~* Intolerance to cow proteins~* Diabetic patients~* Poor understanding of the French language.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 76 Years
- Healthy Volunteers: f

Study Arms:
- Polyamine low-diet (Type: EXPERIMENTAL): Polyamines depleted diet during the week before surgery : 2 cans per day of Polydol (oral alimentation without polyamines), associated to predefined menus low in polyamines
- Liberal alimentation (Type: ACTIVE_COMPARATOR): No specific alimentary diet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prevalence of Secondary Hypogonadism in Male Patients on Chronic Opioid Therapy for Cancer-Related Pain Syndromes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Chronic pain greater than one year.~2. Male.~3. Cancer status must be stable or in remission. For this study, stable disease is defined as identifiable disease at local or metastatic sites that has shown no progression over the previous 3 months and there has been no cancer treatment for ³ 3 months.~4. Patients must be on chronic opioid therapy on a continuous basis in the preceding twelve months with a Morphine Equivalent Daily Dose (MEDD) ³ 200.~5. Age \>/= 18. The questionnaires used in this study have been validated only in the adult population. In addition, some of the questionnaires contain questions of a sensitive nature and are not appropriate in the pediatric population.~6. Patients must be able to understand and sign the consent form.~Exclusion Criteria:~1. Patient who refuses to participate in the study or determined incapable of completing the research.~2. Patients with pre-existing hypopituitarism. Causes include certain tumors (pituitary adenomas, hypothalamic tumors), inflammatory diseases (granulomatous diseases), vascular diseases (postpartum necrosis, carotid aneurysm), traumatic/destructive events (prior surgery, trauma, or radiation), developmental anomalies, infiltration.~3. Patients who tare taking any drugs that may affect the hypothalamic-pituitary-gonadal axis.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Chronic opioid therapy + Gonadal function (Type: None): Males on chronic opioid therapy for cancer-related pain syndromes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Fibromyalgia and Specific Physical Activity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Major patient~* Patient whose FIQ ≤ 59/100~* Patient who can be followed for 12 months in the CETD~* Patient able to follow the adaptated physical activities proposed by Siel Bleu, on the physical and organizational level~* Patient with a smartphone and/or a computer (mac/pc) with an internet connection allowing the use of a tracking application linked to the activity tracker~* Patient with the ability to understand protocol and consenting to participate in this study~* Patient benefiting from a social cover~Exclusion Criteria:~* Patient participating in an interventional trial within 3 months of enrollment~* Pregnant or lactating woman, or having the possibility to procreate without effective contraception~* Patient minor, under guardianship, curators or deprived of liberty~* Patient unable to follow the protocol, according to the judgment of the investigator, or refusing to use of digital applications~* Patient with contraindications to physical activity~* Patient having already followed the physical activities proposed by 'Siel Bleu

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Specific Physical Activity (Type: EXPERIMENTAL): Specific patient care in telephone coaching of fibromyalgia patients.
- Classic Physical Activity (Type: OTHER): Classic patient care in common group of multipathological patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Resident of New Mexico~* Age between the 1 and 95~* Newly diagnosed with cutaneous invasive melanoma; any stage permitted (ICDO C44.0-9) between September 1, 2008 and December 31, 2011.~* SSM (superficial spreading melanoma) and NM (nodular melanoma) histological subtypes are allowed~* Access to a telephone or be able to participate in a personal interview at the clinic~* Physically and mentally competent to complete a 1-hour telephone or personal interview~Exclusion Criteria:~* Ocular melanoma, LMM (lentigo maligna melanoma) or ALM (acral lentigo melanoma), and mucosal melanoma cases.~* No access to a telephone or is not able to meet with the interviewer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Aromatase Inhibitors in the Treatment of Male Infertility

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male partner of a couple presenting for infertility work up after one year of unprotected intercourse~2. Moderate oligozoospermia (defined as mean sperm count ≤ 20 × 106/mL and ≥ than 3 × 106/mL) of at least two separate occasions spanning a minimum of two weeks~3. Obese men BMI ≥ 30~4. FSH and LH levels \< 10 mIU/mL~Exclusion Criteria:~1. Severe Oligozoospermia: Sperm count \< than 3 × 106/mL, including azoospermia~2. Age less than 18 or greater than 65 years~3. Pyospermia or leukospermia: defined by white blood cells ≥ 1 million leukocytes per milliliter of semen~4. Cryptorchidism~5. Vasectomy reversal~6. Regular use of tobacco products~7. BMI \< 30~8. Use of anabolic steroids or testosterone replacement~9. All patients with abnormal initial liver function tests AST or ALT will be excluded form the study

- Gender: MALE
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group B (Type: PLACEBO_COMPARATOR): Placebo
- Group A (Type: EXPERIMENTAL): Anastrozole

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of recurrent multiple myeloma~* Must have received ≥ 2 prior therapies~PATIENT CHARACTERISTICS:~* Performance status 0-3~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Interleukin-6 and Interferon-α (Type: EXPERIMENTAL): Subjects will be started on recombinant interferon-α at a dose of 3 million units SQ daily, escalating the dose by 1 million units every week as tolerated to a maximum dose of 3 million units/m2/day. Following a minimum of one month of interferon therapy with two weeks on a stable dose, subjects will begin recombinant interleukin-6 therapy at a dose of 2.5 ug/kg/day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pneumovitreolysis for Vitreomacular Traction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* able to give written informed consent to the procedure~* diagnosis of symptomatic VMT based on clinical and OCT-findings~Exclusion Criteria:~* any form of retinal tear, macular degeneration, vascular occlusion of the retina, aphakia, high myopia (\> -8 diopters), uncontrolled glaucoma, vitreous opacities, retinal ablation, previous vitrectomy surgery.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pneumatic Vitreolysis (Type: EXPERIMENTAL): All included eyes will receive one intravitreal injection of filtered sulfur hexafluoride gas (SF6).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: [18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged 18 years or greater.~* All patients or legal guardians are willing and able to sign written informed consent and HIPAA authorization in accordance with local and institutional guidelines.~* Enrolled on the FORESEE trial.~* Biopsy proven estrogen receptor positive breast cancer.~* Patient deemed refractory to all combinations of hormonal therapies by FORESEE trial investigators.~Exclusion Criteria:~* Patients with known allergic or hypersensitivity reactions to previously administered radiopharmaceuticals. Patients with significant drug or other allergies or autoimmune diseases may be enrolled at the Investigator's discretion.~* Patients who require monitored anesthesia for PET/CT scanning.~* Patients who are too claustrophobic to undergo PET/CT scanning.~* Patients who are pregnant or currently breast feeding.~* Any patient that is medically unstable defined as a patient requiring inpatient hospitalization or needing evaluation at an acute care or urgent care facility at the time of imaging.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment: all patients (Type: EXPERIMENTAL): One session of \[18F\]FES PET/CT Imaging

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Argon Plasma Coagulation in the Treatment of Patients With Hemoptysis Caused by Endobronchial Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with hemoptysis caused by endobronchial (i.e. identifiable with flexible bronchoscopy) malignancies, without coagulopathy or other medically correctable causes of bleeding, who need endoscopic intervention with Argon Plasma Coagulation to stop bleeding~* Adult patients who are able to tolerate bronchoscopy~* Adult patients who are able to sign the written informed consent for the study participation~Exclusion Criteria:~* Patients with hemoptysis caused by endobronchial malignancies with coagulopathy or other medically correctable causes of bleeding.~* Patients who are not able to tolerate bronchoscopy~* Patients with hemoptysis without identifiable endobronchial malignancies during flexible bronchoscopy~* Patients with Pace-Maker and/or Automated Implantable Cardioverter- Defibrillator(AICD)~* Patients who refuse/are not able to sign the informed consent for the study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hemoptysis patients (Type: None): Hemoptysis patients caused by endobronchial malignancies

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sensorimotor Based Brain Computer Interface

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 or older.~* Able to read text on a computer screen~* Able to understand and remember instructions concerning participation.~Exclusion Criteria:~* Unable give informed consent.~* Unable to understand and follow instructions.~* Have abnormal tone or uncontrolled movements in the head-and-neck that would interfere with EEG recordings.~* Known to have photosensitive epilepsy.~* Open head lesions or sores.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Mu Rhythm with adaptation (Type: EXPERIMENTAL): None
- Mu Rhythm without adaptation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients undergoing autologous peripheral blood stem cell transplant (PBSC) for relapsed/refractory Hodgkin's disease, non-Hodgkin's lymphoma, or patients with myeloma. All patients must meet criteria for transplantation.~Exclusion Criteria:~* Patients with active, invasive/systemic fungal infection.~* Patients who are pregnant or lactating females.~* Patients with active CNS malignant disease or life expectancy limited by diseases other than the disease for which the patient is being transplanted.~* Also, patients cannot have known hypersensitivity to either G-CSF or GM-CSF.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abdomen (Type: ACTIVE_COMPARATOR): These subjects will have their cytokine injections administered only to their abdomen.
- Extremities (Type: ACTIVE_COMPARATOR): The extremity arm will have their injections administered to their upper and/or lower extremities.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic or cytologic diagnosis of prostate carcinoma.~* Subject must have progressive metastatic prostate cancer despite adequate medical or surgical castration therapy. Furthermore, if applicable, medical castration must be maintained for the duration of the protocol.~* Serum testosterone \< 50 ng/ml.~* Subjects who have received anti-androgen therapy with a resulting PSA decline must demonstrate progression following discontinuation of anti-androgen therapy.~* Subjects capable of fathering children must agree to use an effective method of contraception for the duration of the trial.~* Must have previously received docetaxel for prostate cancer~* ECOG performance status 0-2~* Willing and able to give informed consent~Exclusion Criteria:~* Platelet count \<100,000/mm3~* Absolute neutrophil count (ANC) \<1,500/mm3~* Hemoglobin \< 8 g/dL~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2.5 x upper limit of normal~* Bilirubin (total) \>2 x upper limit of normal. Subjects with known Gilbert's syndrome are eligible if direct bilirubin is within normal limits~* For subjects with serum creatinine \> 1.5 x ULN, calculated creatinine clearance \< 30 ml/min are excluded; subjects meeting this exclusion criterion are eligible if a measured clearance is \> 30 ml/min~* Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study~* Prior investigational therapy within 4 weeks of treatment. Furthermore, other investigational anti-cancer therapy is not permitted during the treatment phase.~* Grade \> 1 peripheral neuropathy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All subjects (Type: EXPERIMENTAL): Carboplatin and Paclitaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues